Mizuho Securities Upgrades Selecta Biosciences (SELB) to Buy

Mizuho Securities analyst Difei Yang upgraded Selecta Biosciences (NASDAQ: SELB) from Neutral to Buy with a price target of $8.00 (from $2.50).

The analyst comments "We are upgrading Selecta Biosciences from Neutral to Buy, and increasing our 12-month price target from $2.50 to $8 based on our valuation of Selecta's ImmTOR platform in gene therapy. ImmTOR could enable re-administration of AAV-based gene therapies as well as initial gene therapy dosing for patients with pre-existing AAV antibodies, which would otherwise preclude treatment. We assign a platform valuation of $630 mil to ImmTOR, based on publicly-traded peers with lead gene therapy assets at similar stages of development. Available pre-clinical data in NHP is encouraging, and initial clinical data, expected in 2H21, could further validate this platform and its utility in gene therapy."

For an analyst ratings summary and ratings history on Selecta Biosciences click here. For more ratings news on Selecta Biosciences click here.

Shares of Selecta Biosciences closed at $4.05 yesterday.

You May Also Be Interested In

• BlueScope Steel Limited (BSL:AU) (BLSFY) PT Raised to AUD22.50 at Credit Suisse
• Auto Trader Group PLC (AUTO:LN) (ATDRY) PT Lowered to GBP6.77 at Goldman Sachs
• Nomura/Instinet Upgrades Wipro Ltd. (WPRO:IN) (WIT) to Neutral